These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35495642)

  • 1. HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir.
    Troyano-Hernáez P; Reinosa R; Holguín Á
    Front Microbiol; 2022; 13():854974. PubMed ID: 35495642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic diversity of capsid protein (p24) in human immunodeficiency virus type-1 (HIV-1) variants circulating in the Russian Federation].
    Kuznetsova AI; Munchak IM; Lebedev AV; Tumanov AS; Kim KV; Antonova AA; Ozhmegova EN; Pronin AY; Drobyshevskaya EV; Kazennova EV; Bobkova MR
    Vopr Virusol; 2023 Mar; 68(1):66-78. PubMed ID: 36961237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.
    Troyano-Hernáez P; Reinosa R; Holguín A
    Front Microbiol; 2022; 13():866705. PubMed ID: 35910645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV Transmembrane Glycoprotein Conserved Domains and Genetic Markers Across HIV-1 and HIV-2 Variants.
    Valadés-Alcaraz A; Reinosa R; Holguín Á
    Front Microbiol; 2022; 13():855232. PubMed ID: 35694284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
    Nka AD; Bouba Y; Teto G; Semengue ENJ; Takou DK; Ngueko AMK; Fabeni L; Carioti L; Armenia D; Pabo W; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Fokam J; Ndjolo A
    J Antimicrob Chemother; 2022 Dec; 78(1):272-275. PubMed ID: 36411257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New findings in cleavage sites variability across groups, subtypes and recombinants of human immunodeficiency virus type 1.
    Torrecilla E; Llácer Delicado T; Holguín Á
    PLoS One; 2014; 9(2):e88099. PubMed ID: 24516589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing.
    Tao K; Rhee SY; Tzou PL; Osman ZA; Pond SLK; Holmes SP; Shafer RW
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.
    Bester SM; Adu-Ampratwum D; Annamalai AS; Wei G; Briganti L; Murphy BC; Haney R; Fuchs JR; Kvaratskhelia M
    mBio; 2022 Oct; 13(5):e0180422. PubMed ID: 36190128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
    Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
    Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.
    Tailor MW; Chahine EB; Koren D; Sherman EM
    Ann Pharmacother; 2024 Feb; 58(2):185-195. PubMed ID: 37138515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants.
    Holguín A; De Arellano ER; Soriano V
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1067-74. PubMed ID: 17919099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus.
    Lee NE; Sutherland RK
    Curr Opin Infect Dis; 2023 Feb; 36(1):15-19. PubMed ID: 36753704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.
    Martinez-Picado J; Prado JG; Fry EE; Pfafferott K; Leslie A; Chetty S; Thobakgale C; Honeyborne I; Crawford H; Matthews P; Pillay T; Rousseau C; Mullins JI; Brander C; Walker BD; Stuart DI; Kiepiela P; Goulder P
    J Virol; 2006 Apr; 80(7):3617-23. PubMed ID: 16537629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.
    Fitzon T; Leschonsky B; Bieler K; Paulus C; Schröder J; Wolf H; Wagner R
    Virology; 2000 Mar; 268(2):294-307. PubMed ID: 10704338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensatory substitutions in the HIV-1 capsid reduce the fitness cost associated with resistance to a capsid-targeting small-molecule inhibitor.
    Shi J; Zhou J; Halambage UD; Shah VB; Burse MJ; Wu H; Blair WS; Butler SL; Aiken C
    J Virol; 2015 Jan; 89(1):208-19. PubMed ID: 25320302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.
    Margot N; Vanderveen L; Naik V; Ram R; Parvangada PC; Martin R; Rhee M; Callebaut C
    J Antimicrob Chemother; 2022 Mar; 77(4):989-995. PubMed ID: 35028668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon.
    Ragupathy V; Zhao J; Wood O; Tang S; Lee S; Nyambi P; Hewlett I
    Virol J; 2011 Apr; 8():185. PubMed ID: 21513545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate.
    Larijani MS; Sadat SM; Bolhassani A; Pouriayevali MH; Bahramali G; Ramezani A
    Curr HIV Res; 2018; 16(5):322-337. PubMed ID: 30605062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maturation-induced conformational changes of HIV-1 capsid protein and identification of two high affinity sites for cyclophilins in the C-terminal domain.
    Endrich MM; Gehrig P; Gehring H
    J Biol Chem; 1999 Feb; 274(9):5326-32. PubMed ID: 10026140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.